Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer
نویسندگان
چکیده
منابع مشابه
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
OBJECTIVE To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients. METHODS Within a prospective single-center study, Cap was offered to patients who had already received at least 1 previous treat...
متن کاملFirst line therapy for metastatic pancreatic cancer.
Metastatic pancreatic cancer remains a difficult disease to treat; however, there are more new drug combinations on the horizon each week. We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data.
متن کاملEffect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
BACKGROUND This study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicity, and efficacy of second-line chemotherapy with FOLFIRINOX after gemcitabine (GEM)-based chemotherapy failure in metastatic pancreatic cancer (MPC). METHODS We studied 18 histopathologically proven MPC patients. The schedule was 85 mg/m oxaliplatin, irinotecan, and 400 mg/m leucovorin, followed by...
متن کاملPhase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer.
PURPOSE Despite advances in cancer therapy, treating pancreatic cancer remains one of the major challenges in the field of medical oncology. We conducted this phase II study to evaluate the efficacy and safety of regional hyperthermia combined with gemcitabine for the treatment of unresectable advanced pancreatic cancer. METHODS Eligibility criteria included histologically proven, locally adv...
متن کاملSecond-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?
Gemcitabine (Gemzar) has been the standard treatment for metastatic pancreatic cancer based primarily on clinical benefits. To date, no standard guideline for second-line treatment of pancreatic cancer has been established. Data supporting the use of second-line therapy compared to best supportive care is lacking. We reviewed the published literature on second-line chemotherapy for pancreatic c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Gastroenterology
سال: 2012
ISSN: 1007-9327
DOI: 10.3748/wjg.v18.i12.1357